Close menu




Biotech

Photo credits: pixabay.com

Commented by André Will-Laudien on June 17th, 2025 | 07:05 CEST

Takeovers! A new dawn for biotech companies – Evotec, BioNTech, PanGenomic Health, and CureVac in focus

  • healthtech
  • Biotechnology
  • Pharma

Many large pharmaceutical companies are facing the "patent cliff" as patents on blockbuster drugs expire, threatening massive revenue losses in the future. To fill these gaps, they are acquiring suitable and innovative biotech companies with promising drug pipelines. Sometimes, however, they simply acquire technologies already worth billions. The current wave of acquisitions in the biotech sector is being driven by a combination of economic pressure, technological change toward AI and digitalization, and a weak financing environment for smaller biotech companies. After years of restraint and high volatility, fundamental valuation factors are back in focus. Investors are returning, creating a prosperous environment for those who jump on the bandwagon in time. We highlight a few ideas.

Read

Commented by Armin Schulz on June 16th, 2025 | 07:10 CEST

Benefit from the biotech boom: Why Evotec, BioNxt Solutions & BioNTech could be the next winners

  • Biotechnology
  • Biotech
  • Pharma

The biotech sector is pulsating with unique dynamism while traditional markets are faltering. The drivers are billion-dollar acquisitions, groundbreaking research, and strategic alliances. Large pharmaceutical companies are eagerly securing access to innovations. Analysts agree: strong patent portfolios and innovative partnerships are crucial for future growth. These protect valuable therapeutic developments and enable even smaller players to scale globally. For investors, this robust, capital-rich industry offers enormous opportunities. Those who identify the right innovators early on can reap above-average profits. Three companies embody this momentum: Evotec, BioNxt Solutions, and BioNTech.

Read

Commented by Stefan Feulner on June 16th, 2025 | 07:00 CEST

Novo Nordisk, dynaCERT, Verbio – Do not panic!

  • Hydrogen
  • cleantech
  • Biotechnology
  • Sustainability

No, Donald Trump was not the focus of attention this week, even though the US president invited people to a parade to celebrate his 79th birthday. Instead, the escalating conflict between Iran and Israel dominated the last few days of the trading week. So far, investors seem relatively unimpressed by the flaring conflict. Energy stocks, especially oil producers, have risen sharply, which could signal an end to the correction of the past few months.

Read

Commented by André Will-Laudien on June 13th, 2025 | 07:00 CEST

The three IT musketeers – AI, high tech, quantum computing! NetraMark Holdings, Bayer, Novo Nordisk, and D-Wave

  • AI
  • hightech
  • computing
  • Pharma
  • Biotechnology

A new edition of GTC 2025 is currently underway in the French capital, Paris, where NVIDIA CEO Jensen Huang spoke at length about the future of artificial intelligence. As usual, he also made some interesting comments about quantum computers. In the eyes of the NVIDIA CEO, quantum computer technology has reached a decisive turning point and will soon be able to solve some interesting problems that would take even NVIDIA's most advanced AI systems years of computing time to solve. The requirements go beyond pattern recognition, automation, and real-time decisions. Recently, AI has also been playing a significant role in medicine and pharmaceutical development. For some stocks, there is, therefore, a daily reason to reach new highs. Now is the time for investors to focus!

Read

Commented by Fabian Lorenz on June 12th, 2025 | 07:10 CEST

Short squeeze, hedge funds, and summer rally: Plug Power, Novo Nordisk, Power Metallic Mines

  • Mining
  • Copper
  • Gold
  • Silver
  • Biotechnology
  • Hydrogen

Is Power Metallic Mines poised for a summer rally? There are certainly good reasons to believe so: Following the discovery of its world-class multi-metal project, the stock has consolidated healthily. At the same time, further positive drilling results were reported, followed by a massive expansion of the area this week. Now, an extensive new drilling program is getting underway. Plug Power has shown in recent days how quickly a stock can rise by 50%. The insolvency candidate has delivered several pieces of positive news, and a short squeeze could drive the stock further. At Novo Nordisk, investors are realizing that the sell-off in recent months may have been too severe. The stock is working on a new upward trend. A hedge fund and a partnership in the AI sector are providing tailwinds.

Read

Commented by Nico Popp on June 10th, 2025 | 07:20 CEST

Future market – Worth about USD 50 billion: Illumina, Moderna, PanGenomic Health

  • Healthcare
  • Biotechnology
  • healthtech

Medicine is becoming personal. The era of one-size-fits-all drugs is coming to an end. Experts at BCC Research predict that the market for personalized medicine will grow from USD 54.2 billion in 2023 to USD 100.5 billion by 2028. That represents an annual growth rate of 13.2%. Other analysis firms, such as Grand View Research and Market Research Intellect, confirm this promising outlook for investors. All the more reason to take a closer look at Illumina, Moderna, and PanGenomic Health and explore the opportunities they present for investors.

Read

Commented by Stefan Feulner on June 10th, 2025 | 07:05 CEST

Palantir, NetraMark, Qualcomm – Caution, buy signals!

  • AI
  • Biotechnology
  • computing
  • Software
  • Technology

Artificial intelligence is fundamentally changing the economy. It optimizes processes, reduces costs, and creates new business models. Its use in the healthcare and pharmaceutical sectors is currently developing particularly dynamically. Data-based decisions and personalized medicine are significantly increasing efficiency. According to experts, the global market for AI in healthcare could grow disproportionately in the coming years. Many AI companies are still in the early stages of their development.

Read

Commented by Fabian Lorenz on June 9th, 2025 | 07:15 CEST

BioNTech billion-dollar deal a template for BioNxt Solutions? Bayer shares recommended as a buy!

  • Biotechnology
  • Pharma

The billion-dollar deal between BioNTech and Bristol-Myers Squibb was a real bombshell and has revitalized the biotech industry. While analysts are raising their price targets for the German biotech high-flyer, there are also critical voices. Investors are also wondering where Big Pharma will strike next. One potential candidate for a partnership is BioNxt Solutions. The Company aims to simplify drug administration using oral dissolvable films, skin patches, and tablets. Clinical trials are about to begin on the development of its lead product for the easier treatment of multiple sclerosis, and a key patent has just been granted in Europe. Due to its low valuation and universal application possibilities, a complete takeover is also conceivable. And what is Bayer doing? Despite numerous legal proceedings, the stock is performing well in 2025. Analysts see further upside potential and have upgraded the stock.

Read

Commented by Armin Schulz on June 6th, 2025 | 07:00 CEST

The US healthcare revolution: How are Bayer, PanGenomic Health, and Pfizer positioned?

  • Healthcare
  • Pharma
  • Biotechnology

The US healthcare system is undergoing unprecedented change under Secretary Robert F. Kennedy Jr. Pharmaceutical giants are groaning under drastic price controls and regulatory upheaval, while digital healthcare pioneers are sensing unprecedented opportunities. This systemic shock is tearing down old power structures and catapulting agile players to the forefront – an explosive interplay of risk and opportunity. Those who understand the new rules of the game will discover lucrative prospects amid the chaos. Today, we take a look at Bayer, PanGenomic Health, and Pfizer to see who stands to benefit.

Read

Commented by Fabian Lorenz on June 3rd, 2025 | 07:20 CEST

A bombshell and a buying opportunity! BioNTech, Bayer, and AI stock NetraMark

  • Biotechnology
  • AI
  • Biotech
  • Pharma

Bombshell news from BioNTech. The Company has announced a collaboration for its cancer pipeline - billions in revenue are on the horizon. The stock has surged significantly. Are there other exciting buying opportunities in the biotech and pharma sectors right now? US politics have recently dampened industry sentiment. The Trump administration wants to lower drug prices. One potential beneficiary is NetraMark, as this AI gem helps industry cut development costs and timelines. In addition, takeover speculation could drive the stock in the second half of the year. And what is Bayer doing? The stock has outperformed the DAX in 2025. Are there reasons to consider buying?

Read